TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$1.36 USD
-0.04 (-2.86%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $1.70 +0.34 (25.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Telesis Bio Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 28 | 27 | 11 | 7 | NA |
Cost Of Goods | 11 | 12 | 7 | 3 | NA |
Gross Profit | 17 | 16 | 4 | 4 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 63 | 62 | 40 | 20 | 0 |
Income After Depreciation & Amortization | -47 | -46 | -35 | -16 | 0 |
Non-Operating Income | 2 | -1 | -2 | -1 | NA |
Interest Expense | 3 | 1 | 1 | 1 | NA |
Pretax Income | -48 | -48 | -39 | -18 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -48 | -48 | -39 | -18 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -48 | -48 | -39 | -18 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -43 | -33 | -15 | 0 |
Depreciation & Amortization (Cash Flow) | 16 | 3 | 2 | 2 | NA |
Income After Depreciation & Amortization | -47 | -46 | -35 | -16 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.66 | 1.64 | 1.01 | NA | NA |
Diluted EPS Before Non-Recurring Items | -22.66 | -29.68 | -37.95 | NA | NA |
Diluted Net EPS (GAAP) | -29.50 | -29.68 | -38.49 | NA | NA |
Fiscal Year end for Telesis Bio Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.55 | 3.44 | 6.98 | 5.56 | 8.65 |
Cost Of Goods | 2.35 | 1.99 | 2.23 | 2.57 | 2.96 |
Gross Profit | -0.80 | 1.45 | 4.75 | 3.00 | 5.69 |
SG&A, R&D, and Dept/Amort Expenses | 10.69 | 9.97 | 22.23 | 13.12 | 13.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | -11.49 | -8.52 | -17.48 | -10.12 | -7.97 |
Non-Operating Income | 0.15 | 0.10 | -0.11 | 0.19 | 0.02 |
Interest Expense | 0.21 | 0.22 | 1.84 | 0.68 | 0.33 |
Pretax Income | -11.56 | -8.64 | -17.68 | -10.62 | -8.28 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.56 | -8.64 | -17.69 | -10.63 | -8.29 |
Extras & Discontinued Operations | -1.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.59 | -8.64 | -17.69 | -10.63 | -8.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.73 | 1.67 | 1.67 | 1.67 | 1.66 |
Diluted EPS Before Non-Recurring Items | -7.03 | -5.52 | -4.14 | -6.65 | -5.04 |
Diluted Net EPS (GAAP) | -7.62 | -5.52 | -11.15 | -6.65 | -5.04 |